AMNEAL PHARMACEUTICALS Reports 7.1% Increase in Total Revenue for Fiscal Year 2023 Q2

August 19, 2023

☀️Earnings Overview

AMNEAL PHARMACEUTICALS ($NYSE:AMRX) reported total revenue of USD 599.0 million for the second quarter of the 2023 fiscal year ending on June 30 2023, which is a 7.1% increase from the same period in the prior year. Additionally, net income rose by 109.9% to USD 11.9 million.


After analyzing the company’s financials, GoodWhale has concluded that AMNEAL PHARMACEUTICALS is a medium risk investment in terms of financial and business aspects. GoodWhale has also detected two risk warnings in the company’s income sheet and balance sheet. If you would like to check out these warnings, all you need to do is become a registered user on GoodWhale. From there, you can access detailed information about AMNEAL PHARMACEUTICALS’s financials and make an informed decision about investing in the company. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis
  • About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Amneal Pharmaceuticals. More…

    Total Revenues Net Income Net Margin
    2.31k -2.05 1.1%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Amneal Pharmaceuticals. More…

    Operations Investing Financing
    198.65 -84.82 -93.45
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Amneal Pharmaceuticals. More…

    Total Assets Total Liabilities Book Value Per Share
    3.7k 3.52k 0.98
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Amneal Pharmaceuticals are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    10.0% 147.2% 8.8%
    FCF Margin ROE ROA
    4.9% 57.4% 3.5%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items

  • Peers

    The competition between Amneal Pharmaceuticals Inc and its competitors is fierce. Each company is vying for market share in the highly competitive pharmaceutical industry. Its competitors, Voyageur Pharmaceuticals Ltd, Alkem Laboratories Ltd, and Jeil Pharmaceutical Co Ltd, are all established players in the industry with deep pockets and significant resources. Amneal has been able to gain market share by being nimble and quick to market with new products, but it remains to be seen if it can sustain this growth in the face of stiff competition from its well-entrenched rivals.

    – Voyageur Pharmaceuticals Ltd ($TSXV:VM)

    Voyageur Pharmaceuticals Ltd is a pharmaceutical company with a market cap of 9.67M as of 2022. The company has a Return on Equity of -94.32%. The company develops and manufactures drugs for the treatment of various diseases and conditions.

    – Alkem Laboratories Ltd ($BSE:539523)

    Alkem Laboratories Ltd is a pharmaceutical company with a market cap of 372.17B as of 2022. The company has a Return on Equity of 10.81%. Alkem Laboratories Ltd is engaged in the manufacture and sale of pharmaceutical and Ayurvedic products. The company offers a wide range of products in the areas of cardiology, diabetology, gastroenterology, nephrology, neurology, and psychiatry.

    – Jeil Pharmaceutical Co Ltd ($KOSE:271980)

    Jeil Pharmaceutical Co Ltd is a South Korean company that manufactures and sells pharmaceutical products. The company has a market cap of 255 billion as of 2022 and a return on equity of -7.04%. The company’s products include antibiotics, antifungals, antivirals, and anti-inflammatory drugs. Jeil Pharmaceutical Co Ltd is a publicly traded company listed on the Korea Exchange.


    AMNEAL PHARMACEUTICALS had a lucrative second quarter of 2023, with total revenue of USD 599.0 million and a 109.9% increase in net income to USD 11.9 million. This strong financial performance has been reflected in the stock price, which moved up on the same day as the release of the financial results. Investors may find AMNEAL PHARMACEUTICALS an attractive opportunity, given its strong performance and potential for further growth.

    Recent Posts

    Leave a Comment